Strategic Collaboration withNordicDx

Upfront Diagnostics announced a strategic collaboration with NordicDx in the field of stroke diagnostics. This partnership represents a groundbreaking step in advancing stroke care through innovative diagnostic technology.

NordicDx is starting with an evaluation of Upfront Diagnostics LVOne kits integrated into the NordicDx iaX platform. The iaX is a portable, universal device that reads lateral flow test results in seconds, securely storing data in its portal. Notably, it’s the only globally approved Class 1 medical device for in vitro diagnostics in decentralised use.

The LVOne will significantly expand the NordicDx biomarker menu. For the first time ever, the iaX platform will include GFAP in finger-prick blood—an important biomarker for stroke detection. Additionally, bringing the first lateral flow test for stroke detection to the platform.

The combination of LVOne and iaX will be assessed in real-world clinical trials with stroke patients in the pre-hospital setting. This is an exciting step forward in helping healthcare providers make faster, more accurate stroke diagnoses, where time is of the essence.

Stroke remains a leading cause of disability and death, and with this collaboration, Upfront is dedicated to improving patient outcomes by enabling faster, more precise assessments.

Story by Upfront Diagnostics